Novel molecular biomarkers have the potential to transform much of the current health care model, shifting the focus from a reactive ‘one-size-fits-all’ system to one that is more proactive and precise.
In this new, proactive approach, disease or disease susceptibility may be diagnosed earlier, and disease may be controlled or possibly prevented before it starts; and when disease is detected, new biomarker-based diagnostics may be used to develop treatment strategies which are tailored to the characteristics of individual patients.
In addition to delivering many positive outcomes for cancer patients, biomarkers may have positive economic consequences:
- Regulators and third-party payers may face less risk of adopting cost-ineffective drugs; less variation in patient response and fewer adverse effects will result in savings in the health care system as a whole.
- Developers of therapeutics may reduce financial risks and improve productivity: the cost of developing drugs is expected to decrease and biomarkers are expected to speed drug delivery and the safety and efficacy of those drugs.